28th May 2015 11:21
LONDON (Alliance News) - NetScientific PLC Thursday said that PDS Biotechnology Corp, a company in its portfolio has had positive preliminary data for its lead cancer immunotherapy treatment, PDS0101, which generated a strong response from cells vital to the strength of the human body's immune system in pre-cervical cancer.
According to the biomedical and healthcare technology group, the treatment could offer an alternative to the current practice of surgically removing lesions to deal with pre-cervical cancer.
The results showed that PDS0101 "primes and activates" T-cells, which play a critical and essential role in human immunity, to "recognise, target, and kill" precancerous and cancerous cells that display human papillomavirus viral proteins, which are known to cause cervical cancer.
The company said that people who were tested were "those most likely to develop invasive cancer as they had little to no pre-treatment immune responses to HPV-16.
"PDS Biotechnology's promising results represent an important milestone for the company. The combination of Versamune's powerful and safe profile helps validate its potential to transform treatments for a wide range of cancers and infectious diseases. We now look forward to seeing the Phase II trials begin," Mike Boyce-Jacino, executive director at NetScientific and director of PDS Biotechnology, said in a statement.
NetScientific shares were up 10.1% at 136.50 pence on Thursday.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific